# US 5,702,707 A · Diagnostic method and test kit for the serological detection of the AIDS virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,702,707 A
- Document ID: US5702707A
- Status: Granted
- Kind: A
- Application number: 08/476,555
- Filed: 1995-06-07
- Granted: 1997-12-30
- Earliest claimed: 1986-05-19
- Assignees: Viral Technologies, Inc.
- Inventors: Allan L. Goldstein; Su Sun Wang
- Web page: https://patentgrep.com/patent/US5702707A

## CPC

- C07K 14/005: from viruses
- C07K 16/1143: {Gag-pol proteins, e.g. p17or p24}
- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y10S 435/974: Aids related test
- Y10S 435/975: Kit
- Y10S 530/806: Antigenic peptides or proteins
- Y10S 530/807: Hapten conjugated with peptide or protein
- Y10S 530/826: Viruses
- Y10S 930/221: Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

A peptide of up to about 40 amino acids including the core sequence inclusive of amino acids at positions 92-109 of the p17 gag core protein of HIV-1, such as, Ile-Y.sub.1 -Y.sub.2 -Lys-Asp-Thr-Lys-Glu-Ala-Leu-Y.sub.3 -Lys-Ile-Glu-Glu-Glu-Gln-Asn wherein Y.sub.1 is Asp or Glu, Y.sub.2 is Val or Ile, and Y.sub.3 is Glu or Asp, is effective in inhibiting replication of the HIV virus and provides the basis for a vaccine for treatment or prevention of AIDS.

## Claims

### Claim 1

A peptide of at least about 18 and up to about 40 amino acids including the sequence extending from position 92 to position 109 of the p17 gag protein of HIV-1 and wherein the sequence may be extended from either or both the N-terminal and the C-terminal to include one or more additional consecutive amino acids of the p17 protein of HIV-1, wherein the total number of amino acids in said peptide does not exceed about 40.

### Claim 2 (depends on 1)

A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The peptide of claim 1 which includes as the sequence extending from position 92 to position 109 the sequence: Ile-Y.sub.1 -Y.sub.2 -Lys-Asp-Thr-Lys-Glu-Ala-Leu-Y.sub.3 -Lys-Ile-Glu-Glu-Glu-Gln-Asn
wherein
Y.sub.1 is Asp or Glu,
Y.sub.2 is Val or Ile, and
Y.sub.3 is Glu or Asp.

### Claim 4 (depends on 1)

An immunogenic antigen comprising the peptide of claim 1 covalently bonded to an immunogenic carrier material.

### Claim 5 (depends on 4)

The antigen of claim 4 wherein the immunogenic carrier material is a member selected from the group consisting of albumins, globulins, thyroglobulins, hemoglobulins, hemocyanins, ascaris protein extract, polylysine, polyglutamic acid, lysine-glutamic acid copolymers, lysine-ornithine copolymers, diphtheria toxoid and tetanus toxoid.

### Claim 6 (depends on 4)

A composition comprising the antigenic immunogen of claim 4 and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 4)

The antigen of claim 4 wherein said peptide is labelled for the serological detection of an antibody specific to said antigen.

### Claim 8 (depends on 1)

A monoclonal antibody comprising an antibody specific to the peptide fragment as set forth in claim 1 produced by the fusion of an immortal cell line to an immunoglobulin producing plasma cell producing said specific antibody.

### Claim 9 (depends on 8)

An anti-idiotypic antibody raised against the monoclonal antibody of claim 8.